Company intelligence / Profile preview

DeepQure

Ownership: Private
Development stage: Phase 1

Overview

Early clinical results show significant blood pressure reductions in patients with resistant hypertension. No adverse events reported during or post-procedure. Trials ongoing in South Korea and US.

Therapeutic areas: Cardiovascular
Modalities: Device (laparoscopic-based medical device)Radiofrequency ablation technology
Industry: Therapeutic Medical Devices

Drug pipeline

1 asset

HyperQure

Phase 1

Indications: Resistant hypertension

Partnerships

Seoul National University Hospital (“SNUH”)

Beyond the preview

Go deeper on DeepQure.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DeepQure.

Explore the full profile